Diabetes drug tested to fight antipsychotic weight gain
NCT ID NCT05669742
First seen Feb 06, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This study tests if adding empagliflozin, a diabetes drug, can reduce weight gain and other metabolic problems caused by olanzapine in people with schizophrenia. About 40 adults aged 18-60 who take olanzapine will receive either empagliflozin or a placebo. The main goal is to see if the drug helps control body weight and blood sugar safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta Unuversity
RECRUITINGTanta, 34518, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.